Business
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
LIESTAL, Switzerland & TOKYO, March 11, 2026--Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. ("Neupharma"), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan.
About this update from Curatis Holding Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2953,"height":827,"url":"https://media.zenfs.com/en/business-wire.com/ec1f40266a8aa5b444a3ab2c2a8a28f9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oR_l8q4jW_jm64ebTL5q0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ec1f40266a8aa5b444a3ab2c2a8a28f9","width":960,"height":269},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OJeXcNQQ7gjJmDdxdorM_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ec1f40266a8aa5b444a3ab2c2a8a28f9","width":1200,"height":336}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Japan is one of the world's most important pharmaceutical markets after the US and Europe.","length":94,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug.","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales.","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually.","length":239,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":649,"olType":false},{"type":"text","content":"LIESTAL, Switzerland & TOKYO, March 11, 2026--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. ("Neupharma"), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan.","length":357,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema...